CAR-T Cells in the Treatment of Malignant Hematological Tumors
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
Lymphoma, B-Cell|Leukemia, B-cell|Leukemia, T-Cell|Multiple Myeloma
BIOLOGICAL: CAR-T
Safety: Incidence and severity of adverse events, The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period, 24 months post CAR-T cells infusion
Main research objective: To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary research objective: To investigate the efficacy and cytodynamic characteristics of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors